Key facts
- · Intermediary: Dealmaker Securities LLC · Target: $25K · Maximum: $1.23M · Deadline: 2027-01-08 · Security: Units of the Co-Issuer corresponding with Class C Common Stock of the Issuer · C/A
- · What it is: Progress update · C-U
- · Intermediary: Dealmaker Securities LLC · Target: $25K · Maximum: $5M · Deadline: 2026-05-15 · Security: Units of the Co-Issuer corresponding with Class C Common Stock of the Issuer · C
- · Intermediary: Dealmaker Securities LLC · Target: $25K · Maximum: $5M · Deadline: 2026-05-15 · Security: Units of the Co-Issuer corresponding with Class C Common Stock of the Issuer · C/A
BioXgen Holdings, Inc., based in Tucson, AZ, filed 3 Regulation Crowdfunding offering filings with the SEC, the latest on 2026-04-30, raising through Dealmaker Securities LLC. It set a target of $25K and will accept up to $1.23M. The security offered is units of the co-issuer corresponding with class c common stock of the issuer at $1.43 each. As of its filings the offering is open, with a deadline of 2027-01-08. 4 filings in this family are on record for the company.
Offering filings
| Filed | Intermediary | Target | Maximum | Deadline | Security | Filing |
|---|---|---|---|---|---|---|
| 2026-04-30 | Dealmaker Securities LLC | $25K | $1.23M | 2027-01-08 | Units of the Co-Issuer corresponding with Class C Common Stock of the Issuer | C/A |
| 2026-01-14 | Dealmaker Securities LLC | $25K | $5M | 2026-05-15 | Units of the Co-Issuer corresponding with Class C Common Stock of the Issuer | C |
| 2026-01-14 | Dealmaker Securities LLC | $25K | $5M | 2026-05-15 | Units of the Co-Issuer corresponding with Class C Common Stock of the Issuer | C/A |
Want the whole picture on BioXgen Holdings, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on BioXgen Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BioXgen Holdings, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Financials the company filed
Figures from the C/A filed 2026-04-30, as the company reported them.
| As filed | Most recent fiscal year | Prior fiscal year |
|---|---|---|
| Revenue | $0 | $0 |
| Net income | -$290K | $0 |
| Total assets | $159K | $0 |
| Cash and equivalents | $144K | |
| Short-term debt | $81K | |
| Long-term debt | $362K |
Employees at filing: 0.
Progress updates
2026-02-10, C-U:
The Offering successfully reached its Target Offering Amount on February 9, 2026, having closed on $29,757.91 of funds.
People who signed the filing
- David P. Skinner, President & CEO, Treasurer, Secretary and Director
Every filing
| Filed | What it is | Filing |
|---|---|---|
| 2026-04-30 | Offering amended | C/A |
| 2026-02-10 | Progress update | C-U |
| 2026-01-14 | Offering | C |
| 2026-01-14 | Offering amended | C/A |
A crowdfunding round is won in public. FoxPlug turns your commits, deploys and releases into the posts and visuals that keep the story moving while the offering is open.
Build your launch kitRun a Snapshot on David P. Skinner: other companies, roles and the record behind them. Order Full Report from there if you need more.
Snapshot the foundersTools for this story
Each opens in a new tab, filled in for BioXgen Holdings, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company raising money from the public under Regulation Crowdfunding has to file with the SEC before the offering opens, and has to raise through a single registered intermediary: a funding portal or a broker-dealer. The first filing, Form C, states how much the company is trying to raise, the most it will accept, the deadline, the security and its price, the intermediary and what the intermediary is paid, and two years of the company's own financial figures.
After that the company files amendments when terms change, progress updates as the raise moves, and an annual report each year until it stops reporting. Every row here is one of those filings, linked to the filing itself, so each figure can be checked at the source. Figures are exactly as the company filed them; where a filing leaves a field blank, so does this page. Nothing here is investment advice, and a filing is the company's own statement, not a verification of it.